Shanghai - Delayed Quote CNY

Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SS)

266.47
+2.11
+(0.80%)
At close: 3:00:04 PM GMT+8
Loading Chart for 688506.SS
  • Previous Close 264.36
  • Open 265.99
  • Bid 266.46 x --
  • Ask 266.47 x --
  • Day's Range 262.00 - 269.08
  • 52 Week Range 134.55 - 299.99
  • Volume 724,088
  • Avg. Volume 1,269,740
  • Market Cap (intraday) 106.854B
  • Beta (5Y Monthly) 1.27
  • PE Ratio (TTM) --
  • EPS (TTM) -4.55
  • Earnings Date Apr 30, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, production, and marketing of small molecule chemical, macromolecular biological, and antibody-drug conjugate drugs in China and internationally. Sichuan Biokin Pharmaceutical Co.,Ltd. was founded in 2006 and is based in Chengdu, China.

www.baili-pharm.com

2,521

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688506.SS

View More

Performance Overview: 688506.SS

Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688506.SS
38.98%
SSE Composite Index (000001.SS)
0.87%

1-Year Return

688506.SS
37.30%
SSE Composite Index (000001.SS)
8.36%

3-Year Return

688506.SS
826.85%
SSE Composite Index (000001.SS)
9.61%

5-Year Return

688506.SS
826.85%
SSE Composite Index (000001.SS)
17.86%

Compare To: 688506.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688506.SS

View More

Valuation Measures

As of 5/14/2025
  • Market Cap

    106.01B

  • Enterprise Value

    105.17B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    247.32

  • Price/Book (mrq)

    31.44

  • Enterprise Value/Revenue

    245.71

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    63.67%

  • Return on Assets (ttm)

    53.82%

  • Return on Equity (ttm)

    183.64%

  • Revenue (ttm)

    5.82B

  • Net Income Avi to Common (ttm)

    3.71B

  • Diluted EPS (ttm)

    -4.55

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.75B

  • Total Debt/Equity (mrq)

    53.23%

  • Levered Free Cash Flow (ttm)

    2.69B

Research Analysis: 688506.SS

View More

People Also Watch